Acelyrin, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
SLRN
Acelyrin, INCLeading proxy advisory firm ISS recommends Acelyrin stockholders vote in favor of the proposed merger with Alumis, citing potential upside and uncertainties surrounding alternatives.
SLRN
Acelyrin, INCAlumis and ACELYRIN have agreed to merge, forming a combined entity focused on developing transformative medicines, with ACELYRIN stockholders receiving 0.4814 shares of Alumis for each ACELYRIN share.
SLRN
Acelyrin, INCACELYRIN urges stockholders to vote in favor of the proposed merger with Alumis, citing significant potential upside and value creation for the combined company.
SLRN
Acelyrin, INCDEFM14A: Alumis to Acquire ACELYRIN in All-Stock Merger, Creating Combined Biopharmaceutical Powerhouse
Alumis and ACELYRIN have agreed to merge in an all-stock transaction, aiming to create a leading biopharmaceutical company with a diversified pipeline.
SLRN
Acelyrin, INCAcelyrin appoints Mina Kim as CEO, succeeding Shao-Lee Lin, and announces the departure of Chief People Officer Ron Oyston.
SLRN
Acelyrin, INCACELYRIN, INC. has filed a definitive proxy statement with the SEC, indicating upcoming shareholder actions.
SLRN
Acelyrin, INCACELYRIN, INC. will hold its 2024 annual meeting of stockholders virtually on June 7, 2024, to elect directors and ratify the selection of PricewaterhouseCoopers LLP as its independent accounting firm.